Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society.
ثبت نشده
چکیده
OBJECTIVE To update and expand The North American Menopause Society's evidence-based position on nonhormonal management of menopause-associated vasomotor symptoms (VMS), previously a portion of the position statement on the management of VMS. METHODS NAMS enlisted clinical and research experts in the field and a reference librarian to identify and review available evidence. Five different electronic search engines were used to cull relevant literature. Using the literature, experts created a document for final approval by the NAMS Board of Trustees. RESULTS Nonhormonal management of VMS is an important consideration when hormone therapy is not an option, either because of medical contraindications or a woman's personal choice. Nonhormonal therapies include lifestyle changes, mind-body techniques, dietary management and supplements, prescription therapies, and others. The costs, time, and effort involved as well as adverse effects, lack of long-term studies, and potential interactions with medications all need to be carefully weighed against potential effectiveness during decision making. CONCLUSIONS Clinicians need to be well informed about the level of evidence available for the wide array of nonhormonal management options currently available to midlife women to help prevent underuse of effective therapies or use of inappropriate or ineffective therapies. Recommended: Cognitive-behavioral therapy and, to a lesser extent, clinical hypnosis have been shown to be effective in reducing VMS. Paroxetine salt is the only nonhormonal medication approved by the US Food and Drug Administration for the management of VMS, although other selective serotonin reuptake/norepinephrine reuptake inhibitors, gabapentinoids, and clonidine show evidence of efficacy. Recommend with caution: Some therapies that may be beneficial for alleviating VMS are weight loss, mindfulness-based stress reduction, the S-equol derivatives of soy isoflavones, and stellate ganglion block, but additional studies of these therapies are warranted. Do not recommend at this time: There are negative, insufficient, or inconclusive data suggesting the following should not be recommended as proven therapies for managing VMS: cooling techniques, avoidance of triggers, exercise, yoga, paced respiration, relaxation, over-the-counter supplements and herbal therapies, acupuncture, calibration of neural oscillations, and chiropractic interventions. Incorporating the available evidence into clinical practice will help ensure that women receive evidence-based recommendations along with appropriate cautions for appropriate and timely management of VMS.
منابع مشابه
The North American Menopause Society Statement on Continuing Use of Systemic Hormone Therapy After Age 65.
T he 2012 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) states that hormone therapy (HT) is the most effective treatment for symptoms of menopause. To maximize safety, the initiation of HT should be considered for healthy symptomatic women who are within 10 years of menopause or aged younger than 60 years and who do not have contraindications to use of HT. Co...
متن کاملCardiac autonomic function and vasomotor symptoms: too much break and not enough accelerator?
728 The 2017 hormone therapy position statement of The North American Menopause Society This updated, evidence-based hormone therapy position statement of The North American Menopause Society analyzes the benefi ts and risks of the use of hormone therapy in an individual woman, including age at initiation or time since menopause onset, specifi c formulations or types of hormone therapy, duratio...
متن کاملTreatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
OBJECTIVE To create an evidence-based position statement regarding the treatment of vasomotor symptoms associated with menopause. DESIGN The North American Menopause Society (NAMS) enlisted clinicians and researchers acknowledged to be experts in the field of menopause-associated vasomotor symptoms to review the evidence obtained from the medical literature and develop a document for final ap...
متن کاملThe 2012 hormone therapy position statement of: The North American Menopause Society.
OBJECTIVE This position statement aimed to update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2010 regarding recommendations for hormone therapy (HT) for postmenopausal women. This updated position statement further distinguishes the emerging differences in the therapeutic benefit-risk ratio between estrogen therapy (ET) and combined estroge...
متن کاملModerate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years.
OBJECTIVE This study aims to determine the prevalence and severity of menopausal symptoms in older postmenopausal women and, hence, the need for treatment options for women of this age. METHODS This is a cross-sectional questionnaire-based study conducted between October 2013 and March 2014 among 2,020 women aged 40 to 65 years and living independently across Australia. The main outcome measu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Menopause
دوره 22 11 شماره
صفحات -
تاریخ انتشار 2015